Objectives This study aimed to describe national trends in presentation, management, and outcomes for men with high risk prostate cancer. Methods Data were abstracted from CaPSURE; 10,808 men were diagnosed between 1990 and 2007 and had complete clinical data. High-risk was deWned according to the D'Amico criteria; a more restrictive deWnition assigned clinical stage T2c to intermediate rather than high risk. Temporal trends were assessed for patient distribution among risk groups, and within the high-risk group for individual risk factors, Kattan nomogram score, Cancer of the Prostate Risk Assessment (CAPRA) score, and primary treatment. Survival analysis stratiWed by CAPRA score was performed. Results Under the standard deWnition, 31.2% of the men were diagnosed with high-risk disease, and 16.9% were high-risk under the restrictive deWnition. This proportion has fallen over time but has been stable since 2000. Patients who would be stratiWed to high risk under the standard deWnition and to intermediate risk under the restrictive deWnition have better outcomes than those stratiWed to either intermediate or high risk under both deWnitions. There has been no consistent risk migration within the high-risk group over time. Treatment varies substantially with CAPRA score within the high-risk group, with higher risk men less likely to receive local therapy. Use of androgen deprivation therapy has increased over time, both as primary therapy and in conjunction with both external beam radiation and brachytherapy. Biochemical outcomes vary according to CAPRA score within the high-risk group. Conclusions Clinical stage T2c should not deWne high risk, and the high-risk group should be substratiWed using a multivariable instrument. There is no evidence for meaningful downward risk migration among high-risk patients over the past 15 years. At least some men in the high-risk group may be undertreated.
Introduction
In the United States 27,050 men are expected to die from prostate cancer in 2007, a mortality Wgure which is surpassed by only lung cancer, yet represents a relatively small fraction of the number of men who are diagnosed [1] . Clinician-patient decision making with respect to initial management must therefore consider disease risk-that is, the likelihood of progression to clinical signiWcance and/or mortality-in order that timing and intensity of treatment be appropriately tailored for each patient in the clinic setting, and that patients may be properly identiWed for clinical trials [2] . There exist multiple criteria for deWning high-risk prostate cancer [3, 4] . One of the most widely used risk classiWcation systems, originally published by D'Amico et al. [5] , stratiWes patients to low, intermediate, or high risk based on prostate-speciWc antigen (PSA), biopsy Gleason grade, and clinical T stage.
Under this classiWcation, which is endorsed by the American Urological Association 2007 clinical practice guideline for localized prostate cancer [6] , a patient is assigned to the high-risk group if he has a PSA level >20 ng/ml, a Gleason score 8-10, and/or clinical stagȩ T2c. This classiWcation is based on the 1992 TNM staging system, which stages tumors as T2a for a tumor palpable in less than half of one prostate lobe, T2b for a tumor palpable in more than half of one lobe, and T2c for a tumor palpable bilaterally. Under the 1997 TNM system, which included only T2a and T2b for unilateral and bilateral disease, respectively, we and others considered T2b to stratify patients to intermediate risk, and T3a to stratify them to high-risk disease [7] . The 2002 TNM system returned to the 1992 T2a/b/c system, but it is not clear whether stage T2c should stratify patients to intermediate or high risk.
In this study, we aimed (1) to determine whether patients with T2c are more appropriately stratiWed to intermediate or high risk, (2) to document time trends in risk characteristics and primary treatment strategies, and (3) to assess our ability to substratify patients within the high risk group using the recently validated University of California-San Francisco Cancer of the Prostate Risk Assessment (CAPRA) score [8] .
Methods
Patients were drawn from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry, a longitudinal, observational database of men with biopsyproven prostate adenocarcinoma managed at 31 academicand community-based urology practices across the United States. All prostate cancer patients are recruited consecutively by participating urologists, who report complete workup and treatment data. The data for patients diagnosed before 1995 but still followed by a urologist were initially entered into the database retrospectively; for those whose cancers were diagnosed since 1995, all data entry has been prospective. Completeness and accuracy of the data are ensured by random sample medical record review every 6 months. Additional details of the project methods and a description of the cohort's sociodemographic characteristics have been reported previously [9] .
As of May 2007, 13,740 men had registered and consented in the CaPSURE database; 452 men whose cancers were diagnosed before 1990 were excluded, as were 503 with metastatic and/or locally advanced (clinical stage¸T3bN0M0) disease; 1,977 men with localized disease were missing PSA, clinical T stage, and/or biopsy Gleason score data and were also excluded, leaving 10,808 for analysis. As deWned in the AUA guideline, low-risk patients were deWned as those with clinical stage T1 or T2a, PSA · 10 ng/ml, and a Gleason score of 6. High-risk patients were deWned as those with a PSA level > 20 ng/ mL, a Gleason score of ¸8, and/or a clinical stage of T2c-3a. Others were classiWed as intermediate risk [6] . Additional analyses were performed by means of using a more restrictive modiWcation of the high-risk deWnition, which assigned patients with clinical stage T3a only to high risk, classifying T2c tumors as intermediate rather than high risk.
We analyzed temporal trends in patient distribution among the three risk groups, with time periods deWned to produce relatively even numbers of patients in each group and to focus attention on the current decade; patients who would be stratiWed to high risk under the standard deWnition and intermediate risk under the more restrictive deWnition were evaluated as a separate "intermediate/high" group. Biochemical recurrence-free survival by risk group was assessed using Kaplan-Meier and log-rank analysis. Within the high-risk group (standard deWnition) we further analyzed trends in individual risk factors (PSA, Gleason score, T stage, percent of biopsy cores positive [PPB]).
Risk was further analyzed using two well-validated multivariable instruments; the Wrst is the original Kattan preoperative nomogram [10] , which predicts percent likelihood of biochemical recurrence-free survival at 5 years following surgery on the basis of Gleason score, clinical T stage, and a cubic spline transformation of PSA. The calculation of the score-which is relatively complex-for large numbers of patients in CaPSURE was facilitated by prior collaboration with the nomogram's author [11] . The second instrument, the UCSF Cancer of the Prostate Risk Assessment (CAPRA) score, assigns up to three points for Gleason score, up to four points for categorized PSA level, and one point each for age > 50 years old, clinical stage T3a, and >33% positive of biopsy cores positive. The CAPRA score is thus calculated from 0 to 10, with an every twopoint increase in CAPRA score representing roughly a doubling of risk of biochemical recurrence following prostatectomy [3, 8, 12] .
We analyzed trends over time in primary treatment among low-risk patients; 103 high-risk patients in the analytic dataset (3.1%) were missing data on primary treatment. An additional 43 (1.3%) had primary treatment recorded as "other" or "none" (as opposed to active surveillance, coded in CaPSURE as "watchful waiting") and were also excluded from treatment analyses. The use of neoadjuvant or adjuvant androgen deprivation therapy (ADT) and adjuvant radiation therapy over time was also examined among patients electing radical prostatectomy (RP), brachytherapy, or external-beam radiation therapy (EBRT). Because patients were unevenly distributed across the time periods, statistical signiWcance of temporal trends in risk factors and diagnosis and in primary treatment patterns was assessed using the Cuzick nonparametric test for trend. The variation in primary treatment selection by risk level as measured by the CAPRA score was also assessed.
Finally, we performed survival analysis on high-risk radical prostatectomy patients to predict risk of recurrence (PSA level > 0.2 on two occasions or any second treatment at least 6 months following surgery) stratiWed by the CAPRA score. For this analysis, patients receiving any neoadjuvant (prior to surgery) or adjuvant (treatment within 6 months of surgery) treatment were excluded, as were those with <6 months of follow-up or fewer than two postoperative PSA values available. For this subset (N = 1131), Kaplan-Meier plots were produced, and the log-rank test and Cox proportional hazards regression were used to identify signiWcance of the CAPRA score-as both a continuous and categorized variable-as a predictor of biochemical recurrence. All analyses were performed by using Stata for Macintosh, version 9.2 (Stata Corporation, College Station, TX, USA). Figure 2 illustrates biochemical recurrence-free survival curves for patients stratiWed by risk groups, illustrating that patients stratiWed to high risk by the standard but not the restrictive deWnition actually have better outcomes than those stratiWed to intermediate risk by both deWnitions. The diVerence between these two curves is statistically signiWcant by the log-rank test (P = 0.012). The trend toward more low-and less high-risk disease at diagnosis was signiWcant (P < 0.001) Fig. 2 Biochemical recurrence by risk group. Kaplan-Meier curves are presented for patients stratiWed to low-risk, intermediate-risk, and high-risk, and for those ("Int/High") stratiWed to high risk using the standard deWnition and intermediate risk using the more restrictive deWnition of high risk signiWcant (P < 0.001), but is explained wholly by trends before 2000; scores have fallen slightly since that time (P value for trend since 2000 = 0.07). The trend over time in CAPRA scores was not signiWcant (P = 0.17). Moreover, as illustrated in Fig. 3 , there has actually been a trend towards higher CAPRA scores among high-risk patients since 2000 as assessed by the distribution of scores rather than by the mean score. This trend is statistically signiWcant (P < 0.001).
Results

Using
The CAPRA score can be categorized such that scores 0-2 indicated low risk, scores 3-5 indicate intermediate risk, and scores 6-10 indicated high risk [3, 12] . Over the whole study period, 20.6% of the patients assigned to the high risk group by the standard deWnition had CAPRA scores 0-2, 43.5% had scores 3-5, and 35.9% had scores 6-10. Using the more restrictive deWnition of high risk, the corresponding proportions were 1.0% CAPRA 0-2, 38.4% CAPRA 3-5, and 60.1% CAPRA 6-10. The mean § SD Kattan score among the low risk group was 90 § 3; among the intermediate and high risk groups, the means were 76 § 11 and 60 § 23 using the standard deWnition, and 75 § 12 and 49 § 24 using the restrictive deWnition. Figure 4a shows treatment primary distribution among high risk patients (standard deWnition) over time. Just over 40% of high-risk patients underwent RP as primary treatment. Use of brachytherapy in this group initially rose markedly and since has fallen nearly to early-1990s levels. Use of EBRT has also fallen somewhat over time, while use of primary ADT has risen fairly consistently. Figure 4b illustrates that treatment selection varies considerably Change in distribution of high-risk patients (standard deWnition) across CAPRA scores over time within the standard high-risk group; with increasing risk as assessed by the CAPRA score, patients are less likely to receive RP or brachytherapy and more likely to receive EBRT and especially primary ADT. The use of WW falls with increasing risk. Table 2 gives the rates of use of neoadjuvant and adjuvant ADT and radiation therapy. The major Wndings are that the use of adjuvant radiation following RP is relatively uncommon among high-risk men and has declined over time, and that a growing proportion of high risk men receiving either EBRT or brachytherapy receive neoadjuvant and/or adjuvant ADT. Figure 5 illustrates the Kaplan-Meier curves for biochemical recurrence-free survival among high risk patients (standard deWnition) stratiWed by CAPRA score, and table 3 presents the results of Cox proportional hazards analysis of the ability of the CAPRA score to predict biochemical recurrence as a continuous and categorized variable. The HR of 1.4 for each point increase in CAPRA score corresponds to roughly a doubling of risk of recurrence with each two-point increase in score. Overall, risk of recurrence increases consistently with increasing CAPRA score within the high-risk group; the 5-year recurrence-free survival estimates within the high-risk group range from 83.7 to 25.6% with increasing CAPRA score.
Discussion
Several Wndings merit further comment. First, it seems clear that clinical stage T2c should not be a suYcient Wnding to classify a patient to a high-risk group. Patients stratiWed to high risk based solely on the basis of stage T2c (those labeled "intermediate/high" in Fig. 2 ) in fact had a signiWcantly lower risk of recurrence not only compared to those stratiWed to high risk using the more restrictive deWnition, but also compared to those stratiWed to intermediate risk. Clinical stage in CaPSURE is reported directly by clinicians; one possible explanation is that many patients with unilaterally palpable tumors may be incorrectly reported as stage T2c based on the Wnding of bilateral positive biopsies. It should also be noted that in both the original [10] and revised [13] Kattan preoperative nomograms-based on academic patient cohorts-T2b disease confers higher risk than T2c disease; in the CAPRA analyses, clinical stage conferred no independent information beyond PSA, Gleason score, and PPB until stage T3a [8] . Moreover, under the standard deWnition, over 20% of the high risk group had CAPRA scores in the 0-2 range, indicating low risk disease, and had biochemical recurrence rates similar to D'Amico low risk patients with similar CAPRA scores [14] . Using the more restrictive deWnition, these patients fell to just over 1% of the high-risk group.
We [14] and others [15] have previously found that the downward stage-and risk-migration which was well recognized in the 1990s has slowed considerably in the current decade, with an essentially constant proportion of patients found to have high risk disease since 2000 despite ongoing trends toward lower PSA thresholds for biopsy and higher numbers of cores taken on biopsy. Our prior analysis focusing on low risk patients did Wnd downward risk migration within the low risk group as assessed by the CAPRA score [14] , with ongoing migration in the current decade. The present analysis, conversely, does not conWrm downward migration within the high-risk group; indeed, since 2000 there are trends toward higher risk within the high-risk group as assessed by the Kattan and CAPRA scores. One caveat is that pathologists' practices have changed over the past decade, such that a tumor read in contemporary years is more likely to receive a high grade than the same tumor read in the early 1990s [16] . Table 1 demonstrates that Gleason grade, rather than PSA or clinical stage, is more likely to explain assignment to the high risk group in the latter years of the analysis-so a portion of the rising risk within the high risk group may be an artifact of this change in pathology practice. On the other hand, the proportion of patients presenting with PSA >20 and/or >75% PPB has changed little in the current decade, indicative of a consistent pool of men at high true risk.
We found that the CAPRA score, as a multivariable instrument, was able to substratify the high-risk group eVectively in terms of biochemical recurrence following surgery. Other recent analyses have likewise demonstrated heterogeneity in outcomes among high-risk patients [4] . This increased heterogeneity compared to the low risk group is explainable by the fact that the D'Amico deWnition of high risk does not account for multiple adverse variables. Intuitively, a man with Gleason 4+4, PSA 4.2, clinical stage T1c is at much lower risk than a man with Gleason 4+5, PSA 28.8, clinical stage T2b; both of these men would be in the same high risk group in the 3-level classiWcation, but would be appropriately substratiWed using a multivariable instrument such as the Kattan nomogram or CAPRA score.
It is evident from Wgure 4b that whether or not they are routinely using a multivariable risk prediction instrument, urologists in the community already recognize the additive impact of multiple adverse risk factors. Within the high risk group, treatment patterns vary substantially with multivariable risk as measured by the CAPRA score: utilization of RP and brachytherapy falls markedly with increasing CAPRA score, while utilization of EBRT and primary androgen therapy rises. Evidence from multiple large randomized trials supports the addition of ADT to EBRT [17, 18] . Conversely, ADT does not improve outcomes following RP [19] or brachytherapy [20] , and may adversely impact quality of life outcomes after the latter treatment [21] . Use of primary androgen deprivation monotherapy in CaPSURE has increased consistently among high-risk men. Moreover, utilization of neoadjuvant ADT in association with EBRT for high-risk disease has been over 80% since 2000, but has changed little since that time, whereas utilization in combination with brachytherapy has continued to rise. While concern has been raised regarding possible overtreatment of low risk prostate cancer [14] , these Wgures raise concern regarding possible undertreatment of highrisk disease. High volume centers have reported favorable outcomes after RP monotherapy even among patients with advanced disease [22] , and results may be improved further by addition of adjuvant EBRT for appropriately selected patients. Many patients at the higher end of the risk spectrum with clinically localized disease do not appear to be oVered potentially curative local therapy, and rates of adjuvant EBRT are lower than would be expected after RP for high risk disease.
A few caveats to these analyses should be considered. The data are submitted only by patients and urologists; therefore, any treatments by other practitioners that are not reported by patients may not be captured. Quality assurance mechanisms, including medical record review of all hospital admissions, help to minimize this problem. The CaPSURE practice sites have not been chosen at random and thus do not constitute a statistically valid sample of the United States patient population. However, they represent a broad range of geographic locales and a mix of academic and community sites, which we believe to be the best available sample for the analysis of temporal trends in "real-world" practice. It is possible that the results would have been diVerent with diVerent grouping of the years of diagnosis, but given the consistently strong trends and low p-values realized, this seems unlikely. The CAPRA score has to date been validated only for RP patients, and results of our survival analysis should not yet be extrapolated to patients undergoing other treatments.
In summary, men stratiWed to the D'Amico high-risk category represent a heterogeneous group whose outcomes may be better predicted by a multivariable instrument. Clinical stage T2c alone should not warrant highrisk classiWcation. There is little if any ongoing downward risk migration among high-risk patients, suggesting that new strategies are needed to identify these patients more eVectively and earlier in the disease course. Treatment approaches vary with multivariable risk within the high-risk group, and treatment trends suggest that at least some men with high-risk localized disease treated with ADT monotherapy may be undertreated. Standardization of better deWnitions of risk are needed both for patient counseling in clinical practice and for clinical trial recruitment.
